A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...
The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13. March 10 marked its worst single-day decline in almost two years, plunging 4% as investor ...
SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a $2.9 billion market cap neuroscience company with strong financial health according to InvestingPro data, has granted inducement awards to ...
ACADIA Pharmaceuticals Inc. continues to navigate a complex market environment, balancing the growth of its established products with the development of its pipeline. Trading at an EV/EBITDA ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on central nervous system disorders, has been navigating a complex market landscape with its key products NUPLAZID and ...
EDT Cathie Wood’s ARK Investment buys 35K shares of Recursion Pharmaceuticals (RXRX) todayOptimize Your Investment Research with ...
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a $2.9 billion market cap neuroscience company with strong financial health according to InvestingPro data, has granted inducement awards to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results